Navigation Links
Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
Date:6/18/2012

SAN DIEGO, June 18, 2012 /PRNewswire/ -- Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx's site-specific protein medicinal chemistry technology.

"Ambrx's technology has the potential to provide the foundation for a new family of biologic drug conjugates that selectively deliver small molecules to their site of action," said Peter G. Schultz, Ph.D., a scientific founder and board member. "Merck's deep disease area expertise made it the partner of choice in expanding the application of this technology beyond oncology to other important disease areas."

Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize biotherapeutic drug conjugates directed towards a number of pre-specified targets.  Ambrx will receive an upfront payment of $15 million and is eligible to receive milestone payments totaling up to $288 million for successful discovery, development and commercialization of candidates to all pre-specified targets. In addition, Ambrx will receive royalties on any net sales of products resulting from the collaboration.

"Collaborations are an important part of our strategy to develop a portfolio of next generation protein therapeutics that may offer significant benefits to patients," said Richard Murray, Ph.D., senior vice president and head of biologics and vaccines research at Merck. "This agreement will allow us to combine Ambrx's expertise in site-specific protein conjugation chemistry with Merck's expanding antibody capabilities and extensive small molecule resources."

By combining the targeting properties of biologics with the potent therapeutic properties of small molecules, Merck and Ambrx plan to design and optimize new ways to specifically deliver pharmacologically active compounds to their site of action while minimizing the potential for systemic effects.


'/>"/>
SOURCE Ambrx Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Goddard collaborates with international partners on MMS instrument
2. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
3. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. Computer-designed molecules point to new therapy for cystic fibrosis
7. Bioreactor redesign dramatically improves yield
8. UBM Canon, the Global MedTech Authority, and the Medical Design Excellence Awards Announce Dean Kamen as the Presenter of the 2012 Lifetime Achievement Award
9. Fundamental steps needed now in global redesign of Earth system governance
10. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
11. Systems Alliance Launches Redesigned Website for The Living Legacy Foundation of Maryland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Deep Research Report on Global ... report on the transformer market. The report provides ... industry chain structure as well as industry overview. ... China’s domestic market as well as global industry ... The report also covers information on policy, plans ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW/ - Aequus ... to announce that it has closed a brokered ... warrants for approximately C$3.7 million.  Cormark Securities Inc. ... in the Brokered Offering for a syndicate of ... PI Financial Corp. (collectively the "Agents"). Concurrently with ...
(Date:11/21/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced results ... 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A have ... ended September 30, , Nine-months ended September ... 2014 , 2013 , 2014 , ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... 2014 RPS Diagnostics (RPS®) – ... today announces its third annual partnership of the ... Smart About Antibiotics Week from November 17-23. , ... campaign designed to highlight the coordinated efforts of ... and for-profit partners to provide education about the ...
Breaking Biology Technology:International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... today announced that Alan Krasner, M.D. has been appointed ... "The addition of Dr. Krasner to our team ... we expect him to play an,important role in the ... Chief Executive Officer and Chairman of Biodel. "Dr.,Krasner,s depth ...
... Thoracic Society ... ... 20 ,Patients with asthma not adequately controlled on the inhaled,corticosteroid ... switched to the equivalent dose of,FP combined with salmeterol administered ...
... How Pharma ... Analytics, SOMERVILLE, Mass., May 20 Spotfire, a,division of ... Marcazzo, Senior Director Life Sciences Analytics, will present,Applying Next Generation ... Biotech Conference being held May 20 & 21 in Basel,Switzerland. ...
Cached Biology Technology:Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer 2Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS 2Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS 3TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech 2TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech 3
(Date:11/11/2014)...  Forensicon, Inc., a Chicago -based ... the promotion of Yaniv Schiff from Senior ... Schiff,s new role as Director, he will lead company ... examiners and provide leadership within the company,s digital forensics ... Schiff joined Forensicon in 2006 ...
(Date:11/7/2014)... , November 6, 2014 Leading Biometric ... better mobile security revolutionizing online transactions.  Companies in focus today ... Ltd. (NYSE: BABA ), Google Inc. (NASDAQ: ... eBay Inc. (NASDAQ: EBAY ) and MasterCard Inc. ... and NXTDW), a biometric authentication company focused on the ...
(Date:11/6/2014)... MD, November 6, 2014 - Insilico Medicine, Inc, ... aging and age related diseases announced a research ... of cancer, Champions Oncology, Inc (OTC: CSBR). , ... for personalized medicine, but Champions Oncology,s TumorGraft technology ... validate the chemotherapy regimen experimentally generating vast amounts ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... for step,ATP splitting in membrane protein dynamically measured for ... of Biological Chemistry How a transport protein ... ATP, has been tracked dynamically by RUB researchers. Using ... the bacterial membrane protein MsbA and its interaction partner ...
... Hormone-mimicking chemicals released into rivers have been found to ... has revealed. The controversial chemical BPA, which emits oestrogen-like ... behavior, leading to inter-species breeding. The study, published in ... when the boundaries between species are blurred. ...
... A new strategy to manage invasive species and ... Grand River Grasslands, an area within the North American ... with his colleagues at Iowa State and Oklahoma State ... to establish a more diverse landscape for native wildlife. ...
Cached Biology News:ATP splitting in membrane protein dynamically measured for the first time 2Hormone-mimicking chemicals cause inter-species mating 2Grassroots approach to conservation developed 2Grassroots approach to conservation developed 3
Sterile glass 5 mm beads that make spreading bacterial and yeast cultures easy. Can be washed, autoclaved and reused....
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
Biology Products: